Ultragenyx Faces Class Action Lawsuits Over Setrusumab Drug Efficacy Misrepresentations

Ultragenyx Faces Legal Challenges Over Drug Efficacy Allegations

Ultragenyx Pharmaceutical Inc. is currently embroiled in significant legal challenges following a class action lawsuit related to alleged misrepresentations about the efficacy of its drug candidate, setrusumab. This lawsuit, led by the law firm Levi & Korsinsky, LLP, pertains to investors who purchased Ultragenyx securities between August 3, 2023, and December 26, 2025. They are asserting that the company provided misleading statements regarding the outcomes of the Phase III Orbit and Cosmic studies, particularly concerning setrusumab’s ability to improve clinical outcomes in treating Osteogenesis Imperfecta (OI), a rare bone disorder. As the April 6, 2026, deadline to seek lead plaintiff status approaches, Ultragenyx's operational integrity faces scrutiny from current and prospective investors.

The allegations are particularly concerning in light of Ultragenyx’s disappointing trial results, which revealed that neither the Orbit nor Cosmic studies achieved their primary endpoints. Despite some suggestions of improved bone mineral density from treatment, the absence of significant reductions in fracture rates has raised red flags. Particularly notable was the company’s earlier announcement in July 2025, where interim results indicated failure to meet statistical significance, triggering a sharp 25% drop in stock price that foreshadowed investor unrest. With the subsequent December announcement leading to further declines—where stock value plummeted by over 42%—analysts have begun reassessing the company’s valuation and growth potential, notably adjusting price targets downward by more than 30%.

Transparency and accountability in clinical trial reporting are critical, especially for companies like Ultragenyx that focus on developing therapies for rare diseases. As emphasized by attorney Joseph E. Levi, the case underscores the importance of providing accurate information to shareholders, particularly surrounding risks associated with clinical trial outcomes. The ongoing legal developments highlight a broader concern within the pharmaceutical industry about the ethical implications of misreporting study results.

In addition to the major lawsuit from Levi & Korsinsky, a separate class action has also been initiated by Robbins Geller Rudman & Dowd LLP, targeting the same timeframe and accusations regarding Ultragenyx’s disclosures about setrusumab. As the legal landscape evolves, shareholders affected by these announcements are being encouraged to come forward for compensation, revealing potential new challenges for the pharmaceutical firm in maintaining investor confidence and navigating the complexities of drug approval processes in the future.